Chugai Pharmaceutical Future Growth
Future criteria checks 1/6
Chugai Pharmaceutical is forecast to grow earnings and revenue by 6.2% and 4.4% per annum respectively. EPS is expected to grow by 6.2% per annum. Return on equity is forecast to be 17% in 3 years.
Key information
6.2%
Earnings growth rate
6.2%
EPS growth rate
Pharmaceuticals earnings growth | 23.8% |
Revenue growth rate | 4.4% |
Future return on equity | 17.0% |
Analyst coverage | Good |
Last updated | 21 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,224,223 | 425,265 | 375,458 | 428,567 | 13 |
12/31/2025 | 1,160,101 | 389,690 | 351,336 | 414,183 | 15 |
12/31/2024 | 1,135,976 | 377,369 | 332,760 | 371,800 | 15 |
9/30/2024 | 1,142,350 | 386,964 | 349,434 | 419,416 | N/A |
6/30/2024 | 1,084,570 | 355,041 | 265,465 | 327,068 | N/A |
3/31/2024 | 1,036,076 | 326,373 | 323,991 | 383,090 | N/A |
12/31/2023 | 1,111,367 | 325,472 | 350,827 | 409,925 | N/A |
9/30/2023 | 1,276,051 | 336,745 | 205,825 | 258,712 | N/A |
6/30/2023 | 1,243,437 | 326,969 | 200,169 | 252,605 | N/A |
3/31/2023 | 1,211,632 | 316,154 | 252,376 | 299,319 | N/A |
12/31/2022 | 1,259,946 | 374,429 | 172,873 | 244,112 | N/A |
9/30/2022 | 1,143,716 | 370,791 | 298,989 | 366,072 | N/A |
6/30/2022 | 1,205,696 | 389,011 | 339,236 | 422,551 | N/A |
3/31/2022 | 1,191,496 | 387,359 | 227,919 | 305,626 | N/A |
12/31/2021 | 999,759 | 302,995 | 206,760 | 279,626 | N/A |
9/30/2021 | 887,919 | 256,462 | 180,866 | 256,890 | N/A |
6/30/2021 | 809,055 | 230,577 | 194,361 | 252,664 | N/A |
3/31/2021 | 776,339 | 210,611 | 165,601 | 246,567 | N/A |
12/31/2020 | 786,946 | 214,733 | 143,646 | 205,035 | N/A |
9/30/2020 | 753,853 | 202,590 | 127,482 | 211,422 | N/A |
6/30/2020 | 734,019 | 190,599 | 108,080 | 196,718 | N/A |
3/31/2020 | 711,320 | 174,062 | 116,245 | 178,610 | N/A |
12/31/2019 | 686,184 | 157,560 | 145,464 | 206,641 | N/A |
9/30/2019 | 662,198 | 139,543 | 83,362 | 160,274 | N/A |
6/30/2019 | 614,949 | 113,070 | 43,280 | 118,955 | N/A |
3/31/2019 | 586,648 | 99,631 | 23,827 | 101,309 | N/A |
12/31/2018 | 579,787 | 92,488 | 41,403 | 119,074 | N/A |
9/30/2018 | 572,994 | 85,857 | 91,950 | 125,700 | N/A |
6/30/2018 | 566,548 | 85,285 | N/A | 120,997 | N/A |
3/31/2018 | 556,159 | 82,101 | N/A | 127,695 | N/A |
12/31/2017 | 534,199 | 72,713 | N/A | 107,623 | N/A |
9/30/2017 | 517,908 | 67,704 | N/A | 63,732 | N/A |
6/30/2017 | 497,023 | 58,143 | N/A | 67,355 | N/A |
3/31/2017 | 497,354 | 57,592 | N/A | 49,230 | N/A |
12/31/2016 | 491,780 | 53,592 | N/A | 38,787 | N/A |
9/30/2016 | 492,584 | 56,562 | N/A | 40,808 | N/A |
6/30/2016 | 506,192 | 62,537 | N/A | 39,670 | N/A |
3/31/2016 | 501,649 | 61,043 | N/A | 49,913 | N/A |
12/31/2015 | 498,839 | 61,125 | N/A | 62,918 | N/A |
9/30/2015 | 495,455 | 58,897 | N/A | 75,502 | N/A |
6/30/2015 | 479,265 | 52,220 | N/A | 50,719 | N/A |
3/31/2015 | 454,147 | 46,786 | N/A | 54,919 | N/A |
12/31/2014 | 461,109 | 50,980 | N/A | 37,034 | N/A |
9/30/2014 | 450,545 | 52,461 | N/A | 38,017 | N/A |
6/30/2014 | 444,658 | 55,044 | N/A | 60,556 | N/A |
3/31/2014 | 457,281 | 60,774 | N/A | 54,886 | N/A |
12/31/2013 | 423,652 | 50,895 | N/A | 53,521 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CHGC.F's forecast earnings growth (6.2% per year) is above the savings rate (2.6%).
Earnings vs Market: CHGC.F's earnings (6.2% per year) are forecast to grow slower than the US market (15.4% per year).
High Growth Earnings: CHGC.F's earnings are forecast to grow, but not significantly.
Revenue vs Market: CHGC.F's revenue (4.4% per year) is forecast to grow slower than the US market (9% per year).
High Growth Revenue: CHGC.F's revenue (4.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CHGC.F's Return on Equity is forecast to be low in 3 years time (17%).